OVERVIEW

On the Topic of Topicals: New Treatment Options for Plaque Psoriasis (Online CME/CE Monograph) is organized by MedEdicus LLC.

Course opens: 07/01/2023
Course expires: 07/31/2024

Activity Description and Purpose:
The armamentarium for topical treatment of plaque psoriasis was expanded in 2022 with US Food and Drug Administration approval of 2 nonsteroidal products: tapinarof, 1.0%, cream and roflumilast, 0.3%, cream. Both of these medications are first-in-class topical treatments for plaque psoriasis. Results from clinical trials investigating their safety, efficacy, and tolerability indicate they have features that are important for overcoming the drawbacks of established topical therapies. This educational activity presents information on the mechanism of action of the new nonsteroidal agents, evidence from their premarketing clinical trials, and expert insights on their use in clinical practice. The desired results of this educational activity are for dermatologists and dermatology advanced practice providers to gain knowledge of the newest mechanism of action in psoriasis treatment—aryl hydrocarbon activation—and to review the mechanism of phosphodiesterase-4 inhibition in psoriasis treatment.

Learning Objectives:
After completing this activity, participants will be better able to:

Review clinical efficacy and safety of new topical treatments for plaque psoriasis
Describe the mechanism of action of aryl hydrocarbon receptor agonism in the treatment of plaque psoriasis
Identify strategies to overcome barriers to poor adherence to topical treatments for plaque psoriasis
Apply evidence for topical therapies to individualize treatment for the long-term management of plaque psoriasis